Moderna walked a tightrope trying to convince shareholders it can both develop a new portfolio of drugs and keep costs down in the process.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
AI has a lot of promise in the healthcare industry in areas such as documentation, imaging, and quicker diagnostics as staffing shortages loom.
Data from two promising vaccine trials heralded potential breakthroughs in the treatment of pneumococcal infection and Lyme disease.
The World Health Organization has declared mpox to be a public health emergency, and pharmaceutical and healthcare winners have emerged.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.
WW announced on Thursday that it will be laying off employees and cutting costs to the tune of $100 million per year.
A patent for generative neural network-based ultrasounds from medical device firm Philips could provide more data to develop AI innovations throughout healthcare.
Pfizer, Moderna, and GlaxoSmithKline are developing vaccines for RSV to fill the gap on their balance sheets.
Walgreens’ new leader is planning a rebound for the chain, starting with shuttering a substantial, if unspecified, number of US locations.
The Department of Health announced this week that Medicare is cutting prices for dozens of prescription drugs that have outpaced inflation.
Novo Nordisk scored approval to sell its Wegovy weight loss drug in China. That’s a big win, but competitors will soon flood in.
As the frequency of cyberattacks on healthcare systems and hospitals increases, so too do the costs for preventing them.
A recent trial showed its new 2-for-1 injection was more effective on both illnesses than existing individual shots.
Last year saw the highest private in-patient admissions since records began, totaling roughly 900,000, a 7% increase from 2022.
A loophole lets the company create a back-door offering of a generic drug before the patents of Novo Nordisk and Eli Lilly expire.
Moderna says it was willing to licence the tech but now wants to be repaid by rivals for vaccine revenue generated since then.